We are live on ! Find out more
NVS icon

Novartis

1,087 hedge funds and large institutions have $23.4B invested in Novartis in 2018 Q4 according to their latest regulatory filings, with 143 funds opening new positions, 342 increasing their positions, 403 reducing their positions, and 76 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 143 | Existing positions closed: 76

82% more funds holding in top 10

Funds holding in top 10: 2240 (+18)

34% more call options, than puts

Call options by funds: $108M | Put options by funds: $80.5M

6% more funds holding

Funds holding: 1,0281,087 (+59)

4% more capital invested

Capital invested by funds: $22.4B → $23.4B (+$988M)

0.53% more ownership

Funds ownership: 11.4%11.93% (+0.53%)

15% less repeat investments, than reductions

Existing positions increased: 342 | Existing positions reduced: 403

Holders
1,087
Holders Change
+59
Holders Change %
+5.74%
% of All Funds
24.22%
Holding in Top 10
40
Holding in Top 10 Change
+18
Holding in Top 10 Change %
+81.82%
% of All Funds
0.89%
New
143
Increased
342
Reduced
403
Closed
76
Calls
$108M
Puts
$80.5M
Net Calls
+$27.4M
Net Calls Change
+$1.61M
Name Holding Trade Value Shares
Change
Change in
Stake
MIH
51
Madison Investment Holdings
Wisconsin
$74M -$1.99M -25,599 -3%
EAM
52
Eagle Asset Management
Florida
$73.1M +$723K +9,284 +1%
ClearBridge Investments
53
ClearBridge Investments
New York
$70.8M +$3.66M +47,067 +5%
JWBC
54
John W. Bristol & Co
New York
$68.4M -$4.11M -52,838 -6%
D.E. Shaw & Co
55
D.E. Shaw & Co
New York
$62M +$45.7M +587,157 +267%
MAM
56
Majedie Asset Management
United Kingdom
$56M +$55.5M +712,521 New
Bank of New York Mellon
57
Bank of New York Mellon
New York
$55M +$436K +5,601 +0.8%
Alyeska Investment Group
58
Alyeska Investment Group
Illinois
$53.5M -$14.1M -181,397 -21%
Chevy Chase Trust
59
Chevy Chase Trust
Maryland
$50.4M +$7.97M +102,381 +18%
O
60
OppenheimerFunds
New York
$47.6M +$1.36M +17,478 +3%
Deutsche Bank
61
Deutsche Bank
Germany
$47.5M +$26.1M +335,010 +119%
Millennium Management
62
Millennium Management
New York
$47.3M -$73.3M -941,759 -60%
Envestnet Asset Management
63
Envestnet Asset Management
Illinois
$45.7M +$40.4M +518,939 +686%
MIP
64
Mondrian Investment Partners
United Kingdom
$43.1M -$4M -51,336 -8%
MWNA
65
Marshall Wace North America
New York
$42.9M +$6.43M +82,619 +17%
WRF
66
Waddell & Reed Financial
Kansas
$42.3M +$112K +1,440 +0.3%
DADC
67
D.A. Davidson & Co
Montana
$40.6M +$1.01M +13,020 +3%
Fayez Sarofim & Co
68
Fayez Sarofim & Co
Texas
$40.5M -$5.2M -66,850 -11%
TAM
69
Tocqueville Asset Management
New York
$40.3M -$5.56M -71,448 -12%
Connor, Clark & Lunn Investment Management (CC&L)
70
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$39.5M +$26.5M +340,703 +197%
BC
71
Bartlett & Co
Ohio
$38.7M -$308K -3,957 -0.8%
BCWM
72
Bartlett & Co Wealth Management
Ohio
$38.7M -$308K -3,957 -0.8%
MIS
73
Morningstar Investment Services
Illinois
$37.9M -$2M -25,729 -5%
Capital World Investors
74
Capital World Investors
California
$37.8M
JFL
75
Jarislowsky, Fraser Ltd
Quebec, Canada
$37M -$277K -3,553 -0.7%

NVS Hedge Fund Activity: Q4 2018 in Review

1,087 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2018, worth a combined $23.4B — up 4.4% from $22.4B a quarter earlier.

Buyers outnumbered sellers: 143 funds opened new NVS positions and 76 closed out — a net gain of 67 holders — while 342 added to existing stakes and 403 trimmed.

The largest buyer was BlackRock, adding an estimated $687M. The largest seller was Dodge & Cox, cutting an estimated $657M.

  • 1,087 institutional investors held Novartis (NVS) as of Q4 2018, up from 1,028 in Q3 2018.
  • Funds reported $23.4B of Novartis stock for Q4 2018, up 4.4% quarter-over-quarter.
  • 143 funds opened new Novartis positions in Q4 2018 and 76 closed out, a net change of +67 holders.
  • The largest Novartis buyer in Q4 2018 was BlackRock, an estimated $687M added.
  • The largest Novartis seller in Q4 2018 was Dodge & Cox, an estimated $657M sold.

Based on aggregated 13F filings for Q4 2018.